摘要
目的:研究伊立替康联合替吉奥二线治疗转移性大肠癌的临床疗效及不良反应。方法:对经病理检查确诊同时影像学证实有一个或一个以上脏器转移的36例转移性大肠癌患者,采用伊立替康联合替吉奥方法治疗。替吉奥胶囊80mg/(m2·d),早、晚餐后口服,d1-14。伊立替康60mg/m2,第1、8天。每3周重复,2个周期后评价疗效同时记录不良反应。结果:全组36例病例中CR 2例(5.56%),PR 11例(30.56%),SD 10例(27.78%),PD 13例(36.11%),总有效率36.11%。主要不良反应为乙酰胆碱综合症、延迟性腹泻、中性粒细胞减少、胃肠道反应等,无治疗相关性死亡。结论:伊立替康联合替吉奥二线治疗转移性大肠癌有效率较好,不良反应可耐受,是转移性大肠癌患者较为理想的化疗方案。
Objective：To investigate the clinical curative effects and side effects of second line treatment for advanced colorectal cancer with irinotecan combined with tegafur gimeracil.Methods：All 36 advanced colorectal cancer patients who had one or more than one organ metastasis confirmed by pathological examination as well as imaging examination were treated with irinotecan combined with tegafur gimeracil：Tegafur Gimeracil,with a dose of 80mg/ （m2 · d） by oral administration after breakfast and supper for the first 14 days of a month;And irinotecan,with a dose of 60mg/（m2 · d） on the first day and the eighth day.This was reduplicated every 3 weeks and the curative effects and the adverse reactions were recorded.Results：There were 2 cases of CR（5.56％）,11 cases of PR（30.56％）,10cases of SD （27.78 ％）,13 cases of PD （36.11％） and the total effective rate was 36.11％.The major adverse reactions were acetylcholine syndrome,delayed diarrhea,neutropenia,gastrointestinal reaction and so on,but no treatment -related death.Conclusion：Second line treatment for advanced colorectal cancer with irinotecan combined with tegafur gimeracil is good in effective rate and tolerable in toxic and side effects,this method could be a more ideal chemotherapy regimen for patients with advanced colorectal cancer.
出处
《现代肿瘤医学》
CAS
2013年第11期2511-2513,共3页
Journal of Modern Oncology
关键词
转移性大肠癌
伊立替康
替吉奥
colorectal cancer
irinotecan
tegafur gimeracil
